Berlin-based healthtech startup Oviva announced that it has raised $80M(€67.7M) in its Series C round of funding.
The round was co-led by Sofina and Temasek. Existing investors AlbionVC, Earlybird, Eight Roads Ventures, F-Prime Capital and MTIP, along with several angel investors, also participated.
With this round, the company has now received $115M(€97.4M) in total funds.
Harold Boël, CEO of Sofina, says, “We see great potential in Oviva. Oviva has already made big steps in the right direction in recent years and we believe that this was just the beginning.”
Fund Utilisation
With the proceeds from this round, the company plans to scale its technology and expand its team to 800 employees by the end of 2022.
Additionally, the amount raised will also be directed towards fostering Oviva’s presence in existing and new markets as well as looking at potential M&A opportunities.
“People growth across all functions will be a key focus over the next few months,” Kai Eberhardt, CEO and co-founder of Oviva, points out. “On the one hand, we are keen to enable existing employees to take over more responsibility. And, on the other hand, we are searching for new talent to join us on our journey to help our existing and new patients achieve better health and well-being.”
Special Focus on Europe
Oviva empowers people to change their diet-related habits and thereby improve their long-term health and well-being.
Oviva’s helps treat people with diet-related diseases and helps prevent disease development through diet and lifestyle coaching, combining it with an intuitive app.
The company hires certified dietitians only, thereby ensuring that costs are covered by healthcare systems and insurers.
Their approach is unique in Europe, and is done through close links with healthcare systems, health insurance companies, and doctors.
The company has helped over 200,000 people with diet-related challenges and has formed over 5,000 partnerships with health systems, insurers and doctors.
About Olivia
Oviva was founded in 2014 by – Kai Eberhardt, currently its CEO, Manuel Baumann, CTO, and Mark Jenkins, who is their UK Managing Partner & Medical Director.
Oviva works directly with statutory health insurers and national health systems and operates in the UK, Germany, Switzerland and France.
